The NMDA receptor NR2B subunit: a valid therapeutic target for multiple CNS pathologies.
D000818:Animals; D001665:Binding Sites; D002493:Central Nervous System Diseases / Q000188:drug therapy / Q000378:metabolism*; D003071:Cognition / Q000187:drug effects; D016503:Drug Delivery Systems; D006801:Humans; D018696:Neuroprotective Agents / Q000494:pharmacology* / Q000627:therapeutic use; D010636:Phenols / Q000494:pharmacology; D010766:Phosphorylation; D010880:Piperidines / Q000494:pharmacology; D021122:Protein Subunits / Q000737:chemistry / Q000378:metabolism; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors* / Q000737:chemistry / Q000378:metabolism*; D013329:Structure-Activity Relationship
C121001:NR2B NMDA receptor; D018696:Neuroprotective Agents; D010636:Phenols; D010880:Piperidines; D021122:Protein Subunits; D016194:Receptors, N-Methyl-D-Aspartate; C109643:Ro 25-6981; C095106:traxoprodil mesylate; C010739:ifenprodil